Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Alligator Bioscience

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mitazalimab

            Therapeutic Area: Oncology Product Name: ADC-1013

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 28, 2020

            Details:

            The upcoming Phase II study OPTIMIZE-1 is an open-label, multicenter study evaluating the clinical effect of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with advanced pancreatic cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mitazalimab

            Therapeutic Area: Oncology Product Name: ADC-1013

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 04, 2020

            Details:

            Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATOR-1015

            Therapeutic Area: Oncology Product Name: ATOR-1015

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            The presentations include the phase I study with ATOR-1015, the project ALG-APV-527 which is being developed in collaboration with Aptevo Therapeutics and is ready for clinical phase I studies, and the new bispecific concept Neo-X-Prime.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATOR-1017

            Therapeutic Area: Oncology Product Name: ATOR-1017

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 27, 2020

            Details:

            The Data Review Committee, which monitors the safety of patients in the Phase I study with ATOR-1017, has approved the dose of 100 mg and granted the start of dosing with 200 mg, corresponding to approximately 3.2 mg / kg.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATOR-1017,Mitazalimab

            Therapeutic Area: Oncology Product Name: ATOR-1017

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Positive safety data and Proof of Mechanism data form the basis for the decision to continue two projects in clinical efficacy studies (phase Ib / II) in 2021 evaluating ATOR-1017 and mitazalimab.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mitazalimab

            Therapeutic Area: Oncology Product Name: ADC-1013

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 04, 2020

            Details:

            The results from the study show that a large number of genes are upregulated after treatment with mitazalimab, for example PD-L1, which supports the clinical development plan for mitazalimab which includes combination studies with PD-1 inhibitors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATOR-1017

            Therapeutic Area: Oncology Product Name: ATOR-1017

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            The Data Review Committee that monitors the safety of the patients in the ATOR-1017 Phase I study, has cleared the 40 mg dose and approved to start dosing with the higher dose level of 100 mg, corresponding to approximately 1.6 mg/kg.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mitazalimab

            Therapeutic Area: Oncology Product Name: ADC-1013

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            Alligator plans to submit a CTA, to start a Phase II clinical study. The study (OPTIMIZE-1) is an open multicenter study to evaluate the clinical effect of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with spread of pancreatic cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATOR-1015

            Therapeutic Area: Oncology Product Name: ATOR-1015

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 13, 2020

            Details:

            Interim data from up to 21 cancer patients was presented at the oncology conferences AACR and ASCO, showing a promising safety and tolerability for ATOR-1015. Currently, patients are given doses of 750 mg, approximately 12.5 mg/kg, every two weeks.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATOR-1017

            Therapeutic Area: Oncology Product Name: ATOR-1017

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2020

            Details:

            US Patent Office (USPTO) has issued an approved patent for the drug candidate ATOR-1017, Alligator's wholly owned 4-1BB antibody in clinical development phase I for the treatment of disseminated cancer.

            PharmaCompass